Skip to main content
. Author manuscript; available in PMC: 2017 Aug 22.
Published in final edited form as: J Invest Dermatol. 2016 Nov 1;137(4):819–827. doi: 10.1016/j.jid.2016.10.028

Figure 2. Flowchart of survival analysis inclusion criteria.

Figure 2

All patients with clinical follow-up data were included in survival analysis. For progression-free survival, patients who presented with metastatic disease were excluded from analysis. IHC, immunohistochemistry; MCC, Merkel cell carcinoma; qPCR, quantitative PCR.